Literature DB >> 12616360

Infrainguinal bypass graft patency and limb salvage rates in critical limb ischemia: influence of the mode of presentation.

M K Nasr1, R J McCarthy, J S Budd, M Horrocks.   

Abstract

Rest pain, ulceration, and gangrene are often considered together in studies describing outcomes in patients with critical limb ischemia. A retrospective analysis of prospectively collected data of 152 infrainguinal bypass grafts performed on 128 patients with chronic critical limb ischemia over a 6-year period was carried out. Grafts were classified according to the mode of presentation and were followed up by regular clinical and duplex examinations. Mean follow-up period was 29 months (range 12 to 60 months). Patients' demographics, risk factors, and graft characteristics were not statistically different between the groups. The 5-year cumulative primary patency rates were 33%, 52%, and 51% for gangrene, ulceration, and rest pain, respectively (p = 0.04). The 5-year cumulative primary assisted patency rates were 46%, 70%, and 72% for gangrene, ulceration, and rest pain, respectively (p = 0.01). The 5-year cumulative secondary patency rates were 48%, 76%, and 75% for gangrene, ulceration, and rest pain, respectively (p = 0.003). The 5-year cumulative limb salvage rates were 59%, 87%, and 83%, for gangrene, ulceration, and rest pain, respectively (p = 0.01). Gangrene is a distinct subcategory of critical limb ischemia with a worse prognosis than ulceration and rest pain and should be classified as such when reporting results of infrainguinal bypass grafts.

Entities:  

Mesh:

Year:  2003        PMID: 12616360     DOI: 10.1007/s10016-001-0257-7

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  1 in total

Review 1.  Influence of risk factors and comorbidities on the successful therapy and survival of patients with critical limb ischemia.

Authors:  Mihaela Ioana Constantinescu; Dan Petru Constantinescu; Bogdan Chiş; Aurel Andercou; Ion Aurel Mironiuc
Journal:  Clujul Med       Date:  2013-02-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.